Clinical Trials
4 trialsNCT02340780 2023-08-22
Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
Canadian Cancer Trials Group
Phase 2 Completed
NCT02614508 2019-09-03
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Emory University
Phase 1 Terminated
NCT01833169 2018-10-19
SIGNATURE
Novartis
Phase 2 Completed
NCT01396499 2016-11-01
Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias
M.D. Anderson Cancer Center
Phase 1 Completed